Evidence mapPaperPMID 39759349Full record

ArticleHeliyon2024

Comparison of the efficacy of curcumin and its nano formulation on dexamethasone-induced hepatic steatosis, dyslipidemia, and hyperglycemia in Wistar rats.

Amany M Hamed, Dalia A Elbahy, Ahmed Rh Ahmed, Shymaa A Thabet, Rasha Abdeen Refaei, Islam Ragab, Safaa Mohammed Elmahdy, Ahmed S Osman, Azza Ma Abouelella

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amany M HamedChemistry Department, Faculty of Science, Sohag University, Sohag, Egypt.
Dalia A ElbahyDepartment of Clinical Pharmacology, Faculty of Medicine, Sohag University, Sohag, Egypt.
Ahmed Rh AhmedDepartment of Pathology, faculty of medicine, Sohag University, Sohag, Egypt.
Shymaa A ThabetCentral Research Center, Faculty of Medicine, Sohag University, Sohag, Egypt.
Rasha Abdeen RefaeiDepartment of Physiology, Faculty of Medicine, Sohag University, Egypt.
Islam RagabDepartment of Chemistry, College of Science, Qassim University, Buraidah, 51452, Saudi Arabia.
Safaa Mohammed ElmahdyDepartment of Anatomy, Faculty of Medicine, Sohag University, Sohag, Egypt.
Ahmed S OsmanDepartment of Biochemistry, Faculty of Veterinary Medicine, Sohag University, Sohag, Egypt.
Azza Ma AbouelellaDepartment of Clinical Pharmacology, Faculty of Medicine, Sohag University, Sohag, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective: Insulin resistance is a primary feature of type 2 diabetes. This study compared the effects of curcumin and its nanoformulation on insulin resistance, fasting blood sugar, liver function, GLUT4, lipid profile, and oxidative stress in the liver and pancreas in a diabetic model. Methods: Thirty male Wistar rats were divided into five groups: a control group, a diabetic group, a diabetic group treated with metformin (40 mg/kg), a diabetic group treated with curcumin (100 mg/kg), and a diabetic group treated with curcumin NPs (100 mg/kg). Diabetes was induced by injecting dexamethasone daily for 14 days. Treatment with curcumin and curcumin NPs was administered by gavage for 14 days. Body weight and fasting blood sugar levels were measured on days 1, 14, and 28. Results: The metformin, curcumin, and curcumin NPs groups showed significantly greater body weight gain than the untreated diabetic group (P < 0.001). In diabetic rats treated with curcumin and curcumin NPs, insulin resistance decreased by approximately 40 %, while fasting blood sugar levels dropped by 35-40 % (P < 0.001). The levels of liver enzymes (AST, ALT), cholesterol, triglycerides, LDL, and the oxidative stress marker MDA in liver and pancreatic tissues were reduced by 30-50 %. Additionally, beneficial markers such as albumin, HDL, antioxidants (GSH, SOD), and GLUT4 levels were increased by 25-45 % (P < 0.001). Nano-curcumin consistently showed greater improvements than curcumin, especially in reducing oxidative stress and supporting liver and pancreatic health. Conclusion: This study demonstrates that curcumin NPs has a superior effect on reducing oxidative stress and improving metabolic parameters in diabetes compared to curcumin. by enhancing the bioavailability and stability of curcumin, the nanoformulation showed stronger therapeutic potential for managing high blood sugar, cholesterol issues, and liver health, positioning curcumin NPs as a promising alternative to conventional treatments for diabetes and its complications.

Indexed as

AntihyperglycemicAntihyperlipidemicInsulin resistanceLiver steatosisNano-curcuminType 2 diabetes

Identifiers

PMID39759349
PMCPMC11696662

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.